BioMimetic Therapeutics (BMTI)
BioMimetic Therapeutics Inc.
389-A Nichol Mill Lane
Franklin, TN 37067
United States - Map
Phone: 615-844-1280
Fax: 615-844-1281
Web Site: http://www.biomimetics.com
BioMimetic Therapeutics, Inc. develops and commercializes regenerative protein therapeutic-device combination products. Its products are primarily used for bone and tissue regeneration for the repair and healing of musculoskeletal injuries and conditions affecting bones, tendons, ligaments, and cartilage within orthopedic, spine, and sports injury applications. The companys lead orthopedic product candidate includes Augment Bone Graft, for treating bone defects and injuries. It also has pre-clinical products, which include Augment Injectable Bone Graft for closed non-surgical fracture treatment; TBD for spine fusion; and Augment C for cartilage repair and Augment LT for ligament and tendon repair. The company was formerly known as BioMimetic Pharmaceuticals, Inc. and changed its name to BioMimetic Therapeutics, Inc. in July 2005. BioMimetic Therapeutics, Inc. was founded in 1999 and is headquartered in Franklin, Tennessee

Published:Wed, 04 Aug 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, ......
Published:Mon, 02 Aug 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced that the company will host a webcast conference call on Monday, Augus......
Published:Thu, 29 Jul 2010 05:00:00 -0700
BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medic......
Published:Wed, 04 Aug 2010 07:55:59 -0700
Depomed lead gains among drug stocks a day after it said Pfizer will not file a patent infringement lawsuit to prevent the launch of a painkiller.......
Published:Wed, 04 Aug 2010 08:00:00 -0700
After soaring higher on the FDA approval of its Provenge prostate cancer vaccine in April, volatile Dendreon quickly retreated to well below its pre-approval pricing, but sales fi......
Digg
|
Reddit
|
Mixx
|
del.icio.us
|
Stumble it! |